AIDS biological cellular immunotherapy apparatus

Abstract

The invention discloses an AIDS biological cellular immunotherapy apparatus, and belongs to the field of medicine. The AIDS biological cellular immunotherapy apparatus is characterized in that blood and plasma separators, by which plasma, individual blood cells and multinuclear giant cells formed due to HIV parasitism are prepared; SV40LTag-pcDNA3.1 (-) and pLXSNneo-hTERT recons are constructed; combined transfection is conducted, so as to cause macrophage immortalization; the macrophage, after being subjected to amplification, is prepared in a cell cryopreservation solution until a cell concentration is 80%, and then, a purifier, which is made from a high polymer material, is poured with cells, wherein macrophage cell lines take an effect on phagocytizing HIV; the purifier and the blood and plasma separators constitute a key extracorporeal circulation device; when blood passes through the blood separator, the multinuclear giant cells which contain the HIV are filtered and removed, and subsequently, when plasma, which is separated by virtue of the plasma separator, passes through the purifier, the HIV in the plasma is phagocytized by the macrophage; and the purified plasma is mixed with the individual blood cells separated by virtue of the plasma separator, and then, the mixed plasma and individual blood cells are conveyed back, so that the purification treatment purpose of clearing the HIV inside and outside the blood cells is achieved.

Description

Technical field [0001] The invention relates to the preparation and application of an AIDS biological cell immunotherapy instrument in the medical field, which is mainly used for eliminating HIV in and out of blood cells of AIDS patients, thereby achieving the purpose of treating AIDS. Background technique [0002] AIDS is an infectious disease caused by the Human Immunodeficiency Virus (HIV), which is widespread worldwide. According to the relevant reports of the World Health Organization (WHO) and the UNAIDS, since the first case of AIDS was discovered in the United States in 1981 So far, 208 countries and regions around the world are seriously threatened by AIDS. About 40 million people are infected with AIDS, and the death toll has exceeded 20 million. Every day, about 6000 people become HIV-infected, and about 300 people die every day. In AIDS. The number of HIV-infected persons in China is in a period of rapid growth, and currently far exceeds 1 million. AIDS has become a...

AI Technical Summary

Problems solved by technology

However, the antibody cannot contact the virus remaining in the mononuclear macrophage, and the HIV envelope protein is prone to antigenic variation, and the original antibody loses its effect, so that the neutralizing antibody cannot play its due role

During the latent infection stage, the HIV provirus is integrated into the host cell genome, so HIV will not be recognized by the immune system, so it cannot be eliminated by autoimmunity alone

Another very important reason should be that, based on the mechanism of antibody killing and clearing antigens, it is speculated that after the immune antibody binds to the antigen, if it wants to produce an immune effect, it must either activate the complement and mediate the ADCC effect to dissolve the cellular antigen, but HIV It is not a cellular antigen; either it attracts phagocytes to phagocytize and clear the antigen through chemotaxis, but HIV is protected and proliferates in the phagocytes instead; or the antibody binds to the antigen to neutralize it, making it lose its infectivity, but HIV antigens have many structures Mutations, often making it difficult for antibodies to recognize

[0006] Judging from the current AIDS treatment methods that have been used clinically, the effect is not so ideal: (1) HIV reverse transcriptase inhibitors: can only prevent the infection of susceptible cells that have not been infected with HIV, and have no therapeutic effect on infected cells, and are toxic There are many side effects, including mitochondrial toxicity, myelosuppression, erythrocytic anemia, neutropenia and thrombocytopenia, pancreatitis, and the generation of cross-drug resistance. Drug-resistant variants, resulting in decreased clinical efficacy or failure

(2) HIV protease inhibitors: prone to drug-induced liver injury, lipid metabolism disorders and other side effects and drug resistance

(4) Inhibiting HIV virus entry inhibitors: including blocking the binding of gp120 to CD4, blocking the binding of HIV to coreceptors, acting on gp41 membrane subunits, and acting on CC chemokine receptor 5 (CCR5) on the surface of T lymphocytes to block HIV from entering host cells, but has side effects on the liver and heart

(6) HIV vaccine treatment: Due to the particularity of HIV, such as innate immunity is not enough to resist HIV and its targeted destruction of the immune system, and the virus mutates rapidly, so far no truly safe and effective vaccine has been developed

(7) Gene therapy: HIV gene therapy research has never stopped, including antisense technology, RNA decoy, RNA interference, intracellular antibodies, dominant negative mutants, suicide genes, etc., but gene therapy that has entered phase II clinical trials hardly

[0009] However, there is no report on the construction of macrophage cell lines based on SV40LT and / or hTERT genes and their massive expansion for AIDS treatment

Images